3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
3
Fallopian Tube Neoplasms
3
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Solid Tumor
1
Primary Myelofibrosis
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Metastatic Castration Resistant Prostate Cancer
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Leukemia
1
Leiomyosarcoma
1
Glioblastoma
1
Colorectal Neoplasms
1
Interventions
rucaparib
1
enzalutamide
1
Docetaxel
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Castration Resistant Prostate Cancer
×
rucaparib
×
1 year
×
Clear all
NCT02975934
2025-07-25
TRITON3
pharmaand GmbH
Phase 3
Completed
405 enrolled
34 charts
1 FDA